LBA
ELVN icon

Letko, Brosseau & Associates’s Enliven Therapeutics ELVN Stock Holding History

Letko, Brosseau & Associates’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$376K Buy
+9,600
New +$266K 0.01% 83

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Letko, Brosseau & Associates's ELVN Position: Q1 2026 in Review

Letko, Brosseau & Associates opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 9,600 shares worth $376K. The stake represents 0.01% of the portfolio and ranks #83 among its holdings.

170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Letko, Brosseau & Associates held 9,600 shares of Enliven Therapeutics worth $376K as of Q1 2026.
  • Enliven Therapeutics was a new Letko, Brosseau & Associates position in Q1 2026.
  • Enliven Therapeutics made up 0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #83 holding.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.